Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms.

Blood cancer journal - 4 Jan 2024

Gou Panhong, Liu Duanya, Ganesan Saravanan, Lauret Evelyne, Maslah Nabih, Parietti Veronique, Zhang Wenchao, Meignin Véronique, Kiladjian Jean-Jacques, Cassinat Bruno, Giraudier Stephane

Abstract excerpt

Classical myeloproliferative neoplasms (MPNs) are characterized by the proliferation of myeloid cells and the risk of transformation into myelofibrosis or acute myeloid leukemia (AML) and TP53 mutations in MPN patients are linked to AML. However, JAK2V617F has been reported to impact the TP53 response to DNA damage, suggesting potential overlapping role of TP53 inactivation in MPN. We established a mouse model...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genomics
Share to Interferon-alpha

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Myeloproliferative Disorders

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 38177095
DOI: 10.1038/s41408-023-00969-6
PMCID: PMC10766605

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms.PMID 38177095Read ↗

Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasmsSemantic proximity Read ↗

BMP2/SMAD pathway activation in JAK2/p53-mutant megakaryocyte/erythroid progenitors promotes leukemic transformation.Semantic proximity Read ↗

The JAK2 mutation.Semantic proximity Read ↗

Hematopoietic p53 loss cell-extrinsically defines an immune infiltrated microenvironment in leukemia and pre-leukemiaSemantic proximity Read ↗

Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasmsSemantic proximity Read ↗

Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera.Semantic proximity Read ↗

Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).Semantic proximity Read ↗

Efficacy of JAK1/2 inhibition in murine myeloproliferative neoplasms is not mediated by targeting oncogenic signalingSemantic proximity Read ↗

Inhibition of PLK4 remodels histone methylation and activates the immune response via the cGAS-STING pathway in TP53-mutated AML.Semantic proximity Read ↗

Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms.Semantic proximity Read ↗

Genomic landscape of<i>TP53</i>-mutated myeloid malignanciesSemantic proximity Read ↗

The pathogenesis of therapy-related myeloid neoplasms from TP53-mutant clonal hematopoiesis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.